COG AREN1721 - A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
This Study is
No Longer Enrolling
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 19-1467
More information available at ClinicalTrials.gov: NCT03595124
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers